Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02115022
Other study ID # Col-gastro 5
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 2014
Est. completion date February 2018

Study information

Verified date April 2020
Source Clinical Hospital Colentina
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Accurate staging of patients with pancreatic cancer is critical to avoid the expense, morbidity, and mortality related to unnecessary surgery. While several tests are available for assessing such patients, consensus has not been achieved on the optimal approach. As a matter of fact, pancreatic cancer staging is discussed controversially due to conflicting evidence and certainly EUS has lost grounds due to improvements in CT technology. Thus, the role of EUS and EUS-guided FNA varies among treatment centers.

The present study is designed to better define the role of EUS in predicting resectability, as compared to high resolution cross-sectional imaging.


Description:

Registry procedures:

- HIGH-RESOLUTION PANCREATIC PROTOCOL COMPUTED TOMOGRAPHY (CT) SCAN EXAMINATION: performed on at least 16-section multi-detector row (MD) CT and reviewed using multi-planar reconstructions, with images obtained following the oral administration of water and pancreatic protocol intravenous iopamidol, with images acquired in the pancreatic and portal venous phases of contrast enhancement, reconstructed as thin slice (at 1 mm - pancreatic phase or 2 mm - portal venous phase increments).

- EUS EXAMINATION: performed within 2 weeks of the MDCT, aiming visualization of the pancreas, main surrounding vascular structures, celiac and mediastinal lymph nodes, liver and left adrenal gland, with EUS-FNA performed at the discretion of the investigator/examiner to confirm/exclude metastases and for the confirmation of malignancy in the primary tumor. Patients confirmed by EUS as having distant metastases are to be deferred from the planned surgical intervention.

- SURGICAL INTERVENTION: aiming to provide curative intent (R0) resection.

- HISTOPATHOLOGICAL POSTOPERATIVE STAGING: with evaluation of loco-regional invasiveness and degree of complete surgical resection (R0/R1).

- FOLLOW-UP OF PATIENTS: with phone-calls on an every 6 month basis, for up to 2 years, retaining the following data: survival (or not), date of decease and its direct cause (if applicable), the presence of tumor recurrence (or not).


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date February 2018
Est. primary completion date January 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- adult (= 18 years of age) patients;

- the presence of a confirmed pancreatic mass (suspected neoplastic) deemed resectable or borderline resectable on multislice (at least 16 simultaneously acquired slices) pancreatic protocol computed tomography (CT);

- patients fit and willing to undergo surgery with a curative (R0) intent;

- sign of the informed consent.

Exclusion Criteria:

- the presence of significant co-morbidities that contraindicate pancreatic resection;

- previous neo-adjuvant oncologic therapy;

- distant metastases;

- lack of discernment;

- refusal to sign the informed consent..

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Romania Fundeni Clinical Institute Bucharest
Romania Gastroenterology Department, Clinical Hospital Colentina Bucharest
Romania University Military Hospital Bucharest
Romania Iuliu Hatieganu University of Medicine Cluj Napoca
Romania Research Center in Gastroenterogy and Hepatology Craiova Dolj

Sponsors (4)

Lead Sponsor Collaborator
Clinical Hospital Colentina Institutul Clinic Fundeni, Iuliu Hatieganu University of Medicine and Pharmacy, University of Medicine and Pharmacy Craiova

Country where clinical trial is conducted

Romania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Staging capability of each study procedure Each imaging test (MDCT and EUS) and findings at or after surgery are to be judged on their ability to provide descriptions of the primary tumor's size, location, relationship to vessels - using the terms abutment (=180º of contact) and encasement (>180º of contact), vessel occlusion, variant vascular anatomy, a grade regarding local tumor resectability (resectable, borderline resectable, or locally advanced; R0 or R1 resection), and extent and location of extrapancreatic disease. Up to 2 weeks, depending on the time of the surgical intervention
Secondary Side-effects related to the EUS examination Each patient will be monitored for 24 hours after the EUS examination to identify possible early complications of the procedure Monitored for 24 hours after EUS
Secondary Patient survival time, and tumor recurrence-free survival Each patient is going to be followed-up for up to 2 years after the surgical intervention an an every-6 month basis, in order to identify events such as death or tumor recurrence. Up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05209074 - Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma Phase 1
Not yet recruiting NCT05529940 - NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) Phase 3
Terminated NCT02345460 - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study Phase 2
Recruiting NCT02243007 - Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT05679050 - Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Withdrawn NCT01694589 - A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer Phase 0
Active, not recruiting NCT03138720 - Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Phase 2
Completed NCT01298011 - Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer Phase 2
Completed NCT06363084 - A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Recruiting NCT04810910 - Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Phase 1
Completed NCT01992705 - Borderline Pancreas Study: FOLFIRINOX +SBRT Early Phase 1
Recruiting NCT05624918 - A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma Phase 2
Completed NCT02047513 - Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer Phase 2
Recruiting NCT03492671 - Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer Phase 2
Terminated NCT05546411 - A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer Phase 2
Not yet recruiting NCT06172036 - Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab Phase 2
Recruiting NCT05788744 - Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer N/A
Recruiting NCT04737551 - Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
Recruiting NCT03822936 - Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma Phase 2
Completed NCT03435536 - Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer N/A